Posts Tagged ‘nasdaq’

Pharmasset Inc. (VRUS) jumps on drug findings

Tuesday, September 6th, 2011

Pharmasset Inc. (Nasdaq: VRUS) shares rose 5.2% to $67.55 after the drug developer released preliminary findings from a study of its Hepatitis C treatment. Volume for the stock was 658,000 shares, or about half its daily average.

A news release out September 6 noted that the Princeton, New Jersey-based company announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously.

In all, 95 treatment-naive patients with HCV genotype 1 were enrolled into two open-label arms of the PROTON trial, receiving either PSI-7977 200 mg QD (N=48) or 400 mg QD (N=47) for 12 weeks. Individuals in both arms received Peg-IFN/RBV for 24 weeks and were followed post-treatment to assess SVR12.

What’s more, 26 subjects were enrolled in a placebo control arm and are receiving 48 weeks of Peg-IFN/RBV. Results from this study through the SVR12 endpoint are scheduled to be presented as part of a Presidential Plenary Session at the American Association for the Study of Liver Diseases (AASLD) meeting on Tuesday, November 8, 2011.

“I am very pleased with the results of this study which clearly demonstrate the benefit of the 400 mg dose of PSI-7977 with only 24 weeks of interferon for all subjects,” Dr. Eric Lawitz, the study’s principal investigator, was quoted in the release as saying. “HCV therapy is becoming overly complex, and the elimination of 24 weeks of interferon and ribavirin as well as all response guided criteria for patients with HCV genotype 1 would be a welcomed simplification.”

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.

Fresh Market Inc. (TFM) jumps on better earnings

Wednesday, August 31st, 2011

Fresh Market Inc. (Nasdaq: TFM) shares advanced 11.6% to $38.88 after the grocery chain raised its outlook for 2011 earnings. Volume for the stock topped 942,000 shares, whereas it normally trades around 651,000 for a single day.

A news release out August 31 declared that the company announced unaudited sales and earnings results for its second quarter ended July 31, 2011. In the second quarter of fiscal 2011, net sales increased 13.6% to $259.5 million and comparable store sales increased 4.6%, compared to the corresponding period in 2010. Net income in the second quarter of fiscal 2011 was $10.5 million, compared to pro forma net income of $6.9 million in the corresponding period in 2010. Diluted earnings per share in the second quarter of fiscal 2011 was $0.22, compared to pro forma diluted earnings per share of $0.14 in the prior-year period, an increase of 52.1%.

The same release had CEO Craig Carlock as saying, “We are happy to report another healthy quarter of both sales and earnings growth. Our comparable store sales grew 4.6 %, and this marked our seventh consecutive quarter of comparable sales growth of 4.0% or greater. As revenues grew, we also continued to expand our margins. In the second quarter, we increased our operating margin from 5.2% last year to 6.5% this year despite pressure from rising food and commodity costs and despite the additional costs incurred related to being a publicly-traded company. Additionally, we were excited to open five new stores and to relocate one existing store during the quarter and we are happy with their performance so far.”

Carlock concluded, “We are pleased with the momentum in the business through the first half of fiscal 2011, and even with recent macroeconomic uncertainty, we are increasing our EPS guidance from a range of $1.01 to $1.05 to a range of $1.03 to $1.06.”

The Fresh Market, Inc. based in Greensboro, North Carolina, is a high-growth specialty retailer

Response Genetics, Inc. (RGDX) wins new assignment, stock soars

Wednesday, August 31st, 2011

Response Genetics, Inc. (Nasdaq: RGDX) shares hiked 10.6% to $2.40, on word of a new contract. Volume for the stock was a mere 500 shares, in contrast to a daily average of 12,000.

A news release out August 31 declared that XIFIN Inc., the company revolutionizing revenue cycle management for diagnostic service providers, announced today that Response Genetics had implemented XIFIN’s revenue cycle management system to optimize billing and claims management and help manage cash collections.

The release quoted David O’Toole, Vice President and CFO at Response Genetics as saying, “We believe XIFIN’s expertise in molecular diagnostic billing best positioned us to effectively manage RGI’s cash flow while bringing billing and collections in-house during a period of tremendous company growth and also to meet the stringent regulatory requirements for public companies.”

The Los Angeles-based Response Genetics, Inc., a leading developer of molecular diagnostic tests for cancer including ResponseDX: Lung(TM), ResponseDX: Colon(TM) and ResponseDX: Gastric(TM), has implemented XIFIN’s revenue cycle management system to optimize billing and claims management and help manage cash collections.

Zillow Inc. (Z) stock climbs on quarterly numbers

Thursday, August 25th, 2011

Zillow Inc. (Nasdaq: Z) shares gained 19.9% to $31.49, a day after the online real-estate information provider reported its first quarterly financial results since going public in late July. Volume for the stock came in at 436,000 shares, just nosing out its full-day average.

A news release posted August 24 reported quarterly revenues increased 116% to $15.8 million from $7.3 million in the second quarter of 2010.

Marketplace revenues increased 269% to $9.7 million from $2.6 million in the second quarter of 2010. Display revenues increased 30% to $6.1 million from $4.7 million in the second quarter of 2010.

GAAP net income for the second quarter 2011 was $1.6 million, compared to a net loss of $2.0 million in the same period a year ago and a net loss of $0.8 million in the first quarter of 2011.

Said CEO Spencer Rascoff in the same piece, “The second quarter was outstanding for Zillow® with record revenues, traffic and mobile usage. It marks our first profitable quarter on a GAAP net income basis and our fourth consecutive profitable quarter on an Adjusted EBITDA basis. We’re extremely pleased with our progress and rapid growth, yet we believe we’ve only scratched the surface of our opportunity.”

The Seattle-based Zillow calls itself the leading real estate information marketplace, providing vital information about homes, real estate listings and mortgages through its website and mobile applications, enabling homeowners, buyers, sellers and renters to connect with real estate and mortgage professionals best suited to meet their needs.

Avago Technologies Limited (AVGO) posts strong Q3 results, stock spikes

Wednesday, August 24th, 2011

Avago Technologies Limited (Nasdaq : AVGO) shares raced ahead 8.9% to $31.87 Wednesday, a day after announcing strong third-quarter results. Volume for the stock topped 3.3 million, already surpassing its daily average of 2.7 million.

A news release issued August 23 pointed to net revenue of $603 million, an increase of 10% from the same quarter last year.

Gross margin was $297 million, or 49.3% of net revenue. This compares with gross margin of $263 million, or 47.8% of net revenue in the same quarter last year.

Third quarter net income was $144 million, or $0.57 per diluted share. This compares with net income of $123 million, or $0.50 per diluted share in the same quarter last year.

The same release quoted Avago CEO Hock Tan as saying, “During the third quarter of fiscal 2011, our four target markets performed as we expected and we outperformed these markets as our revenue growth for the quarter came in at the high end of guidance.

“While uncertainties prevail in the global economy today, we continue to believe revenue will grow for the balance of the fiscal year due to share gains with certain wireless and wired OEMs.”

Avago Technologies Limited, based in San Jose, California, is a leading designer, developer and global supplier of a broad range of analog semiconductor devices with a focus on III-V based products.